

Group 2: Initial Course 2 (IC-2)





^{*} For dose modification, refer to Section 8.5

IC-2 consists of:

- Oral prednisone (PRED) 40mg/m² in three divided doses for 3 days every week, weeks 8-13.
- Vinblastine (VBL) 6mg/m²/dose i.v. bolus on day 1 of week 8, 9, 10, 11, 12, and 13.

Further therapy depends on Response at week 13:

- ⇒ Patients with NAD and those with AD better proceed to *continuation therapy*.
- ⇒ Patients with AD intermediate or worse in non-risk organs, proceed to **STRATUM II**.
- ⇒ Patients who develop risk organ involvement under systemic therapy (very unlikely scenario) have to proceed to **STRATUM III** or **STRATUM IV** depending on physician's choice or donor availability. Please discuss such unusual SS-LCH cases with your National Coordinator.